Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche

Pharmaceuticals Division sales were up 11% for the year

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche

FY Revenues: 61.5 billion CHF (+8%)

FY Earnings: 14.1 billion CHF (+30%)

Comments: Pharmaceuticals Division sales were up 11% to CHF 48.5 billion, driven by recently launched products led by multiple sclerosis medicine Ocrevus, the new haemophilia medicine, Hemlibra and cancer medicines Tecentriq and Perjeta, offsetting the impact of competition from biosimilars for MabThera/Rituxan and Herceptin in Europe and Japan (decline combined CHF 1.2 billion) and MabThera/Rituxan, Herceptin and Avastin in the U.S. (estimated decline CHF 0.3 billion). Diagnostics Division sales increased 3% to CHF 12.9 billion. In December, Roche completed the $4.3 billion acquisition of Spark Therapeutics.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters